Medical Doctor Program year 2025 Reported 2020–2025 Source: CMS Open Payments, 2026 publication

Sumit Baral

Vascular & Interventional Radiology East Brunswick, NJ Medical Doctor

NPI 1295153146 CMS profile 8801066

483 Cranbury Rd, East Brunswick, NJ 08816

Open in the dashboard

General payments

$4,082

61 records reported · program years 2020–2025

Research payments

$0

Paid to them · None reported · program years 2020–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Sumit Baral of East Brunswick, NJ is reported in the CMS Open Payments database as having received $4,082 across 61 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 60th percentile of Vascular & Interventional Radiology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

6 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,769 25
2024 General $832 17
2023 General $1,123 13
2022 General $145 1
2021 General $87 2
2020 General $126 3

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Sumit Baral
  • Vascular & Interventional Radiology median
  • Middle half of Vascular & Interventional Radiology
  • National median

In program year 2025, general payments to Sumit Baral were reported at $1,769. Among 3,393 Vascular & Interventional Radiology profiles paid that year, the median was $534 and the middle half received between $166 and $2,075.

Show as a table
Year Sumit Baral Vascular & Interventional Radiology median Middle half National median
2019 $0 $422 $125–$1,555 $163
2020 $126 $200 $68–$652 $114
2021 $87 $280 $99–$866 $132
2022 $145 $433 $137–$1,497 $149
2023 $1,123 $506 $152–$2,019 $160
2024 $832 $556 $175–$1,930 $164
2025 $1,769 $534 $166–$2,075 $169

Breakdown

Who paid General payments · program years 2020–2025
  1. Inari Medical, Inc. $833 12 payments
  2. Boston Scientific Corporation $581 8 payments
  3. Surefire Medical, Inc. $545 8 payments
  4. Penumbra, Inc. $527 8 payments
  5. Stryker Corporation $507 10 payments
  6. Sirtex Medical Inc $475 3 payments
  7. Balt USA, LLC $275 3 payments
  8. Argon Medical Devices, Inc. $81 2 payments
  9. Medtronic Vascular, Inc. $64 1 payment
  10. Cardinal Health 200, LLC $63 2 payments
  11. Other $132 4 payments

Every payment, record by record

What the payments were for General payments · program years 2020–2025
  1. Food and Beverage $4,018 60 payments
  2. Education $64 1 payment
Products named General payments · program years 2020–2025
  1. FLOWTRIEVER CATHETER, S $940 15 payments
  2. CT THROMBECTOMY SYSTEM KIT $811 13 payments
  3. TRINAV INFUSION SYSTEM $545 8 payments
  4. Indigo System $505 7 payments
  5. SIR-Spheres Microspheres $328 2 payments
  6. Prestige Coil System $275 3 payments
  7. FLOWTRIEVER $161 3 payments
  8. LAVA LES (Liquid Embolic System) $147 1 payment
  9. OPTABLATE $125 2 payments
  10. EkoSonic $98 1 payment
  11. Other $840 18 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Billing to Medicare

Part B · data year 2024 · 173 billing codes

Paid by Medicare

$220,498

Of which drugs: $3,093

Medicare patients

1,753

Average age 74

Services billed

32,912

947 women, 806 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 53%
Diabetes 48%
Ischemic heart disease 47%
Chronic kidney disease 36%
Heart failure 32%
Atrial fibrillation 29%
COPD 29%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml Q9967 Office 266 27,330 $2,823
Injection, gadoterate meglumine, 0.1 ml A9575 Office 15 2,832 $270

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

61 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Vascular & Interventional Radiology in New Jersey

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record